About Kura Oncology (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.95 per share
Price / Book5.39
Return on Equity-53.40%
Return on Assets-44.08%
Frequently Asked Questions for Kura Oncology (NASDAQ:KURA)
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology, Inc. (NASDAQ:KURA) posted its earnings results on Tuesday, November, 7th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.01. View Kura Oncology's Earnings History.
Where is Kura Oncology's stock going? Where will Kura Oncology's stock price be in 2017?
5 brokerages have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $16.00 to $19.00. On average, they expect Kura Oncology's stock price to reach $17.75 in the next year. View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. Cann analysts commented, "Loss per share was $0.38, compared to our estimated loss of $0.49. This was the result of lower than estimated operating expenses of $9.5 million compared to our estimate of $9.9 million, which resulted in a net loss 4.2% lower than we estimated; and 23% more shares outstanding from an equity offering in the quarter. There were no other remarkable variances in the quarter. Our outlook for 2017-2022 is being adjusted for higher shares outstanding. Our net income estimates for 2018-2022 remain basically unchanged. We are increasing our estimated shares outstanding by approximately 23% in each of these years. We have adjusted our 2017 outlook to reflect the higher shares outstanding and slightly lower estimated operating expense." (11/8/2017)
- 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (10/18/2017)
Are investors shorting Kura Oncology?
Kura Oncology saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,004,902 shares, an increase of 36.6% from the October 13th total of 1,467,694 shares. Based on an average daily volume of 423,794 shares, the short-interest ratio is currently 4.7 days. Currently, 9.3% of the shares of the company are short sold.
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include Amarin Corporation PLC (AMRN), Epizyme (EPZM), Flexion Therapeutics (FLXN), Omeros Corporation (OMER), Intra-Cellular Therapies (ITCI), Audentes Therapeutics (BOLD), Retrophin (RTRX), Revance Therapeutics (RVNC), CytomX Therapeutics (CTMX), Five Prime Therapeutics (FPRX), Raptor Pharmaceutical Corp (RPTP), La Jolla Pharmaceutical Company (LJPC), Akebia Therapeutics (AKBA), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Aduro Biotech (ADRO), Aclaris Therapeutics (ACRS) and Alder BioPharmaceuticals (ALDR).
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Troy E. Wilson Ph.D. J.D., Chairman of the Board, President, Chief Executive Officer (Age 48)
- Heidi Henson CPA, Chief Financial Officer, Secretary (Age 50)
- Annette North, Senior Vice President, General Counsel (Age 49)
- Pingda Ren Ph.D., Senior Vice President - Chemistry and Pharmaceutical Sciences (Age 46)
- Liu Yi Ph.D., Chief Scientific Officer (Age 47)
- Antonio Gualberto M.D. Ph.D., Chief Medical Officer (Age 50)
- Steven H. Stein M.D., Director (Age 50)
- Faheem Hasnain, Independent Director (Age 58)
- Robert E. Hoffman, Independent Director (Age 51)
- Thomas R. Malley, Independent Director (Age 47)
Who owns Kura Oncology stock?
Kura Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.95%), EAM Investors LLC (0.70%), Alethea Capital Management LLC (0.56%), Artal Group S.A. (0.36%), Iguana Healthcare Management LLC (0.30%) and Bank of New York Mellon Corp (0.21%). View Institutional Ownership Trends for Kura Oncology.
Who bought Kura Oncology stock? Who is buying Kura Oncology stock?
Kura Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., EAM Investors LLC, Artal Group S.A., Iguana Healthcare Management LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, Nationwide Fund Advisors and Alethea Capital Management LLC. View Insider Buying and Selling for Kura Oncology.
How do I buy Kura Oncology stock?
Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of Kura Oncology stock can currently be purchased for approximately $15.90.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $462.30 million. The company earns $-27,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Kura Oncology employs 25 workers across the globe.
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (KURA)MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Kura Oncology (NASDAQ:KURA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$17.75 (11.64% upside)|
Consensus Price Target History for Kura Oncology (NASDAQ:KURA)
Analysts' Ratings History for Kura Oncology (NASDAQ:KURA)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/16/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$18.00||N/A|
|11/9/2017||Citigroup Inc.||Boost Price Target||Buy||$15.00 -> $19.00||N/A|
|9/7/2017||Cowen and Company||Initiated Coverage||Outperform||Medium|
|8/10/2017||Leerink Swann||Reiterated Rating||Outperform||$16.00 -> $18.00||High|
|1/22/2016||JMP Securities||Initiated Coverage||Outperform||$24.00||N/A|
Earnings History and Estimates Chart for Kura Oncology (NASDAQ:KURA)
Earnings History by Quarter for Kura Oncology (NASDAQ KURA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Kura Oncology (NASDAQ:KURA)
2017 EPS Consensus Estimate: ($1.63)
2018 EPS Consensus Estimate: ($2.19)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kura Oncology (NASDAQ:KURA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Kura Oncology (NASDAQ KURA)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Kura Oncology (NASDAQ KURA)
|-$0.34 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter|
www.americanbankingnews.com - November 22 at 7:10 PM
|Oppenheimer Holdings, Inc. Reiterates "$18.00" Price Target for Kura Oncology, Inc. (KURA)|
www.americanbankingnews.com - November 18 at 1:38 PM
|Kura Oncology, Inc. (KURA) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - November 15 at 1:46 AM
|Short Interest in Kura Oncology, Inc. (KURA) Rises By 36.6%|
www.americanbankingnews.com - November 13 at 3:34 AM
|BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co|
www.reuters.com - November 11 at 3:49 PM
|Kura Oncology to Host Investor Day on November 16, 2017|
finance.yahoo.com - November 11 at 3:49 PM
|Leerink Swann Weighs in on Kura Oncology, Inc.'s FY2017 Earnings (KURA)|
www.americanbankingnews.com - November 10 at 2:42 PM
|Kura Oncology, Inc. (KURA) to Post FY2017 Earnings of ($1.52) Per Share, Oppenheimer Holdings Forecasts|
www.americanbankingnews.com - November 10 at 2:34 PM
|Kura Oncology, Inc. (KURA) Releases Earnings Results, Misses Estimates By $0.01 EPS|
www.americanbankingnews.com - November 8 at 4:44 PM
|Kura Oncology's (KURA) "Buy" Rating Reiterated at Cann|
www.americanbankingnews.com - November 8 at 9:50 AM
| Analysts Expect Kura Oncology, Inc. (KURA) to Post -$0.37 EPS|
www.americanbankingnews.com - November 3 at 1:38 PM
|Technical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics ...|
www.prnewswire.com - November 3 at 1:32 PM
|Technical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics Pharma, Regeneron Pharma, and Seattle Genetics|
www.bizjournals.com - November 3 at 1:32 PM
|Kura Oncology to Report Third Quarter 2017 Financial Results|
finance.yahoo.com - November 1 at 5:06 AM
|Oppenheimer Holdings Comments on Kura Oncology, Inc.'s Q1 2018 Earnings (KURA)|
www.americanbankingnews.com - October 31 at 11:42 AM
|Kura Oncology, Inc. (KURA) to Release Quarterly Earnings on Monday|
www.americanbankingnews.com - October 30 at 1:50 PM
|Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML|
finance.yahoo.com - October 29 at 6:02 AM
|Kura Oncology (KURA) Says Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update|
www.streetinsider.com - October 28 at 7:34 AM
|Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update|
finance.yahoo.com - October 28 at 7:34 AM
|Kura Oncology, Inc. (KURA) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - October 21 at 2:42 AM
|Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and|
www.nasdaq.com - October 17 at 12:55 AM
|Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference|
finance.yahoo.com - October 16 at 7:52 PM
|Kura Oncology, Inc. (KURA) Expected to Announce Earnings of -$0.37 Per Share|
www.americanbankingnews.com - October 15 at 2:06 AM
|Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX|
finance.yahoo.com - October 5 at 7:37 AM
|Short Interest in Kura Oncology, Inc. (KURA) Increases By 58.9%|
www.americanbankingnews.com - September 29 at 1:56 AM
|Kura Oncology, Inc. (KURA) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - September 26 at 2:44 AM
|Is It Time To Buy Kura Oncology Inc (KURA)?|
finance.yahoo.com - September 21 at 9:27 AM
|Keep An Eye On These Biotech Stocks This Month, If Invested|
www.rttnews.com - September 18 at 5:22 AM
|Kura Oncology, Inc. (KURA) Short Interest Update|
www.americanbankingnews.com - September 17 at 1:20 AM
|3 Reasons Momentum Stock Investors Will Love Kura Oncology (KURA)|
finance.yahoo.com - September 13 at 4:22 AM
|Kura Oncology, Inc. (KURA) Research Coverage Started at Cowen and Company|
www.americanbankingnews.com - September 10 at 9:54 AM
|Kura Oncology Inc. (KURA) Is Up Sharply On Phase 2 Study Results|
www.nasdaq.com - September 10 at 12:50 AM
|Stocks to Watch: Equifax, Pfizer, Kroger, Southwest, Kura Oncology, American Outdoor Brands|
finance.yahoo.com - September 9 at 3:41 AM
|After-Hours Movers 09/07: (KURA) (ZUMZ) (RDFN) Higher; (AOBC) (FNSR) (EFX) Lower (more...)|
www.streetinsider.com - September 8 at 5:31 AM
|Kura Oncology Inc. (KURA) Is Climbing On Phase 2 Study Results|
www.rttnews.com - September 8 at 5:31 AM
|Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer|
finance.yahoo.com - September 8 at 12:29 AM
| Analysts Anticipate Kura Oncology, Inc. (KURA) Will Post Earnings of -$0.41 Per Share|
www.americanbankingnews.com - September 2 at 2:14 PM
|Kura Oncology, Inc. (KURA) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - September 1 at 10:34 PM
|Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference|
finance.yahoo.com - August 29 at 3:32 PM
|Q3 2017 Earnings Forecast for Kura Oncology, Inc. (KURA) Issued By Leerink Swann|
www.americanbankingnews.com - August 18 at 6:42 AM
|Reviewing Auris Medical Holding AG (EARS) & Kura Oncology (KURA)|
www.americanbankingnews.com - August 10 at 4:32 PM
|Leerink Swann Analysts Lift Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)|
www.americanbankingnews.com - August 10 at 7:06 AM
|Oppenheimer Holdings Analysts Cut Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)|
www.americanbankingnews.com - August 10 at 7:06 AM
|Kura Oncology Announces Commencement of Public Offering of Common Stock|
finance.yahoo.com - August 10 at 1:20 AM
|FY2020 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Lowered by Analyst|
www.americanbankingnews.com - August 9 at 3:02 PM
|Kura Oncology, Inc. (KURA) Issues Quarterly Earnings Results|
www.americanbankingnews.com - August 8 at 11:14 AM
|Kura Oncology, Inc. (NASDAQ:KURA) PT Set at $13.00 by Citigroup Inc.|
www.americanbankingnews.com - August 8 at 10:06 AM
|Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study|
finance.yahoo.com - August 7 at 7:46 PM
|Kura Oncology to Report Second Quarter 2017 Financial Results|
finance.yahoo.com - July 31 at 7:42 PM
|FY2017 EPS Estimates for Kura Oncology, Inc. (KURA) Cut by Analyst|
www.americanbankingnews.com - July 20 at 10:06 AM
Kura Oncology (NASDAQ KURA) Chart for Thursday, November, 23, 2017